Smoking Cessation - Pipeline Insight, 2024

This “Smoking Cessation- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Smoking Cessation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Smoking Cessation Overview

Smoking cessation refers to the process of quitting smoking, a significant health decision that can drastically improve overall well-being and reduce the risk of numerous diseases, including cardiovascular diseases, chronic obstructive pulmonary disease (COPD), and lung cancer. Despite the addictive nature of nicotine, many individuals attempt to quit due to growing awareness of the associated health risks. Governments and health organizations globally promote smoking cessation through public health campaigns, providing resources such as quitlines, counseling, and pharmacological aids to increase the chances of success.

Quitting smoking often triggers withdrawal symptoms, which can be both physical and psychological. Common signs include intense cravings for nicotine, irritability, anxiety, difficulty concentrating, and restlessness. Physical symptoms may include headaches, increased appetite, weight gain, and digestive discomfort. These symptoms tend to peak within the first few days after quitting and gradually diminish over time, usually subsiding within a few weeks. However, the psychological dependence on nicotine may last longer, making relapse a common challenge.

Nicotine, a highly addictive substance found in tobacco, is the primary cause of smoking addiction. Once nicotine enters the bloodstream, it stimulates the release of dopamine, a neurotransmitter associated with pleasure and reward, which reinforces the habit of smoking. Over time, the body builds a tolerance to nicotine, leading to increased consumption to achieve the same effects. Diagnosis of nicotine dependence is often based on self-reported symptoms, including the inability to cut down on smoking, cravings, and withdrawal symptoms. Healthcare providers may use tools such as the Fagerström Test for Nicotine Dependence to assess the severity of addiction.

Several evidence-based treatments are available to support individuals in quitting smoking. Behavioral interventions such as counseling, cognitive-behavioral therapy (CBT), and support groups are commonly used to address the psychological aspects of addiction. Pharmacological treatments, including nicotine replacement therapy (NRT), varenicline (Chantix), and bupropion (Zyban), can help reduce cravings and withdrawal symptoms. Combining both behavioral and pharmacological approaches tends to be the most effective strategy for long-term cessation. Additionally, mobile apps, quitline services, and digital programs offer accessible support for those seeking to quit smoking.

"Smoking Cessation- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smoking Cessation pipeline landscape is provided which includes the disease overview and Smoking Cessation treatment guidelines. The assessment part of the report embraces, in depth Smoking Cessation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smoking Cessation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation R&D. The therapies under development are focused on novel approaches to treat/improve Smoking Cessation.

Smoking Cessation Emerging Drugs Chapters

This segment of the Smoking Cessation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Smoking Cessation Emerging Drugs

• Cytisinicline: Achieve Life Sciences
  • Cytisinicline (cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Cytisinicline dual-acting MOA specifically targets the α4β2 nicotine receptor. Its partial agonist/partial antagonist activity is believed to help reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking.
  • The α4β2 nicotinic receptor is a well-understood target in addiction. When nicotine binds to this receptor, it causes dopamine to be released, reinforcing the dopamine reward system. This receptor has been implicated in the development and maintenance of nicotine dependence. Cytisinicline is believed to act as a partial agonist, preventing nicotine from binding and releasing dopamine. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with smoking cessation
    
    
• EMB-001: Embera Pharmaceuticals
  • EMB-001 is a patented combination product that includes two FDA-approved medications: metyrapone, a cortisol synthesis inhibitor, and oxazepam, a benzodiazepine. This approach is based on the understanding of how stress influences addiction. The main objective of addiction treatment is to achieve long-term abstinence while reducing the likelihood of relapse. Relapses can be triggered by three primary factors: stress (such as family conflicts), cues (like seeing drug paraphernalia), and drug exposure (even minimal contact can reactivate addiction). These triggers often provoke stress responses, leading to the theory that managing these pathways may help mitigate all three relapse causes.
  • By combining these two medications, which affect different elements of the stress response at lower doses, EMB-001 may offer greater effectiveness than either drug alone. A therapy that effectively tackles these barriers and fosters long-term abstinence and recovery would be a major breakthrough in treating a wide range of addictions. The drug is in Phase II stage of development.
    
    
• SBP-9330: Camino Pharma
  • SBP-9330, a small molecule that was discovered by Cosford and his team at Sanford Burnham Prebys. SBP-9330 targets a receptor called metabotropic glutamate receptor 2 (mGlu2), which leads to reduced levels of glutamate - a neurotransmitter linked to nicotine addiction and relapse behavior. SBP-9330 is a positive allosteric modulator (PAM) of mGlu2 and thus represents a new class of drugs for treating substance use disorders. Currently, the drug is in the Phase I stage of its development for the treatment of Smoking Cessation disorders.

Smoking Cessation: Therapeutic Assessment

This segment of the report provides insights about the different Smoking Cessation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Smoking Cessation

There are approx. 10+ key companies which are developing the therapies for Smoking Cessation. The companies which have their Smoking Cessation drug candidates in the most advanced stage, i.e. Phase III include, Achieve Life Sciences.

Phases

The report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Smoking Cessation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Smoking Cessation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smoking Cessation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smoking Cessation drugs.

Smoking Cessation Report Insights

• Smoking Cessation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Smoking Cessation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Smoking Cessation drugs?
• How many Smoking Cessation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smoking Cessation?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Smoking Cessation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Achieve Life Sciences
• Embera Pharmaceuticals
• Camino Pharma
• NFL Biosciences
• Astraea
• Antidote Therapeutics
• Mydecine Innovations

Key Products

• Cytisinicline
• EMB-001
• SBP 9330
• NFL-101
• AT-1001
• ATI-3009
• MYCO-001